Acute promyelocytic leukemia cost-effectiveness of therapy

Jump to: navigation, search

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia cost-effectiveness of therapy

CDC on Acute promyelocytic leukemia cost-effectiveness of therapy

Acute promyelocytic leukemia cost-effectiveness of therapy in the news

Blogs on Acute promyelocytic leukemia cost-effectiveness of therapy

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

A limited number of cost-effective studies have been done. In summary, these studies showed that all-trans retinoic acid-based therapy is more cost effective than chemotherapy.

Cost-effectiveness of therapy

A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.

References

  1. 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.

Linked-in.jpg